Vanda Reports Positive Results for Tradipitant in Study on GLP-1–Induced Nausea and Vomiting

Vanda Pharmaceuticals Inc. announced positive topline results from a randomized, controlled clinical study evaluating tradipitant, an oral NK-1 receptor antagonist, for reducing nausea and vomiting associated with Wegovy® (semaglutide) use in overweight and obese adults.

Study Design and Primary Outcome

The study (VP-VLY-686-2601) pre-treated participants with either tradipitant or placebo for one week before administering a 1 mg dose of Wegovy®, a level normally reached after nine weeks of dose escalation.

• Vomiting occurred in 29.3% of participants receiving tradipitant (17/58)
• Compared with 58.6% in the placebo group (34/58)
• p = 0.0016

This represents a 50% relative reduction, meeting the study’s primary endpoint.

Secondary Outcome

The trial also met a key secondary endpoint assessing both vomiting and significant nausea (≥3 on a 0–5 scale):

• 22.4% in the tradipitant group (13/58)
• 48.3% in the placebo group (28/58)
• p = 0.0039

Safety

Tradipitant demonstrated a safety profile consistent with previous studies, and no new safety signals were identified.

Full Endpoint Summary

*Primary endpoint
**Key secondary endpoint

Context and Implications

Nausea and vomiting are among the most common reasons for GLP-1 receptor agonist discontinuation, with real-world rates estimated at 30–50%. Reducing these effects could help patients continue treatment long enough to achieve meaningful weight loss and metabolic benefits.

Vanda noted that the current findings align with tradipitant’s performance in previous motion-sickness studies, where it reduced vomiting by more than 50% across multiple trials involving over 800 participants.

The global market for GLP-1 therapies exceeded $50 billion in the first three quarters of 2025.

Next Steps

The Phase II study enrolled 116 overweight or obese adults (BMI 25–40 kg/m²) with no prior GLP-1 exposure. Participants were treated for one week before and one week after receiving the single Wegovy® dose, with outcomes collected through daily patient-reported assessments.

Vanda plans to assess the regulatory pathway for tradipitant in this indication and expects to begin a Phase III program in the first half of 2026.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!